Search

Displaying results 2041 - 2050 of 4575 in total
  1. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc. … Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization

  2. Drug

    Olanzapine

    go.drugbank.com/drugs/DB00334
    ApprovedInvestigational

    [A177011] Olanzapine was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.[T548]

  3. Drug

    Isometheptene

    go.drugbank.com/drugs/DB06706
    Approved

    Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.

  4. Drug

    Reserpine

    go.drugbank.com/drugs/DB00206
    ApprovedWithdrawn

    It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.

  5. Drug

    Indalpine

    go.drugbank.com/drugs/DB08953
    ApprovedWithdrawn

    It was initially marketed by Pharmuka. … However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.

  6. Drug

    Lorazepam

    go.drugbank.com/drugs/DB00186
    ApprovedInvestigational

    [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. … The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]

  7. Drug

    Safrazine

    go.drugbank.com/drugs/DB09253
    ApprovedWithdrawn

    In 1960, it was used as an antidepressant but it is now discontinued.

  8. Drug

    Lixisenatide

    go.drugbank.com/drugs/DB09265
    ApprovedInvestigational

    It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763]

  9. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration

  10. Drug

    Fomivirsen

    go.drugbank.com/drugs/DB06759
    ApprovedWithdrawn

    It was discovered by scientists at the National Institutes of Health (NIH) and was first developed by _Isis Pharmaceuticals_ and subsequently licensed to _Novartis_ [A31990]. … Fomivirsen is marketed under the trade name Vitravene for intravitreal injection and was the first antisense drug to be approved by the Food and Drug Administration (FDA).